Product/Composition:- | Sofosbuvir |
---|---|
Strength:- | 400 mg |
Form:- | Film-coated Tablets |
Reference Brands:- | SovaldiĀ® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sofosbuvir 400 mg Tablets are oral direct-acting antivirals used in combination regimens for treating chronic Hepatitis C. Manufactured under EU-GMP and USFDA-compliant facilities, they are available for B2B supply, tenders, and licensing with full CTD dossiers and bioequivalence data to support registration in regulated markets.
Sofosbuvir Tablets are direct-acting antiviral agents (DAAs) used in combination therapy for the treatment of chronic Hepatitis C (HCV) across multiple genotypes. A nucleotide analog NS5B polymerase inhibitor, Sofosbuvir is available in 400 mg strength and forms the backbone of several pan-genotypic HCV regimens. Manufactured under EU-GMP or USFDA-approved facilities, Sofosbuvir is ideal for B2B licensing, tender supply, and distribution in regulated and semi-regulated markets. Offered with full CTD dossier, bioequivalence data, and stability studies, it supports rapid registration and commercialization in global markets. Available as a standalone API or FDF with partner molecules.